Is SPRY or SUPN more undervalued in 2026?

CirclFi compares ARS Pharmaceuticals, Inc. (SPRY) and Supernus Pharmaceuticals, Inc. (SUPN) using 13 institutional-grade valuation models. SPRY has a Quality of Company score of 4.7/10 while SUPN scores 7.8/10.

Which is a better buy — SPRY or SUPN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SPRY and SUPN valuations compare?

SPRY at $9.07 and SUPN at $46.18 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SPRY vs SUPN Valuation Comparison 2026 — Intrinsic Value Analysis

SPRY

Pharmaceutical Preparations

ARS Pharmaceuticals, Inc.

Quality

4.7

out of 10

Value Trap

SAFE

Price

$9.07

Last close

Models

8/13

Active

SUPN

Pharmaceutical Preparations

Supernus Pharmaceuticals, Inc.

Quality

7.8

out of 10

Value Trap

LOW

Price

$46.18

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	SPRY Fair Value	SPRY Upside	SUPN Fair Value	SUPN Upside
Bayesian DCF	Intrinsic	$1.86	-79.5%	$17.17	-62.8%
Earnings Power Value	Intrinsic	—	—	$16.57	-64.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$1.53	-83.1%	$10.76	-76.7%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SPRY vs SUPN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SPRY vs SUPN — Which Stock Is More Undervalued?

SUPN scores higher with a 7.8/10 quality rating vs SPRY's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ARS Pharmaceuticals, Inc. (SPRY) and Supernus Pharmaceuticals, Inc. (SUPN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SPRY currently trades at $9.07 with a QOC of 4.7/10, while SUPN trades at $46.18 with a QOC of 7.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).